Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice

This publication has 23 references indexed in Scilit:

• Single 270 μg kg⁻¹‐dose rFVIIa vs. standard 90 μg kg⁻¹‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison
  Haemophilia, 2007
• Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface
  Journal of Thrombosis and Haemostasis, 2007
• A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
  Journal of Thrombosis and Haemostasis, 2006
• Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review
  Critical Care Medicine, 2005
• The use of recombinant factor VIIa in the treatment of bleeding disorders
  Blood, 2004
• A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®)
  Journal of Thrombosis and Haemostasis, 2003
• The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  Disease-a-Month, 2003
• Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity
  Proceedings of the National Academy of Sciences, 2001
• Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors
  Thrombosis and Haemostasis, 1998
• Platelet activity of high‐dose factor VIIa is independent of tissue factor
  British Journal of Haematology, 1997